Perspectives on Nonmedical Switching and the COVID-19 Pandemic: A Narrative Review
This review describes the impact of nonmedical switching of biologic therapies on US patients and providers, with a focus on switching to in-class alternatives.
Top GLP-1 Agonists Balance Weight Loss Efficacy, Safety
MRD Status Prior to Allo-HSCT Shows Strong Prognostic Value in AML, MDS
Robin Glasco on Addressing Systemic Bias in Data by a Foundation on Building Equity
Pain May Be Indicator of MS Prior to Disease Onset: Study